Patents Examined by Janet L Coppins
  • Patent number: 11166911
    Abstract: The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 9, 2021
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Samarth Kumar, Soni Maheshkumar Parasmal, Milan Mohanbhai Vasoya, Prashant Kane, Subhas Balaram Bhowmick, Rajamannar Thennati
  • Patent number: 11154558
    Abstract: The use of direct factor Xa inhibitors, administered in a dose sufficient to reduce the activity of factor Xa to about 25% less than normal or lower, has the effect of preventing the onset of atherosclerosis, and stabilizing atherosclerotic lesions, and preventing the occurrence or recurrence of atherosclerotic events.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: October 26, 2021
    Assignee: Adams Pharmaceuticals LLC
    Inventors: Jonathan Adams, Peter Jeffrey Adams
  • Patent number: 11141401
    Abstract: An embodiment of the invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected, from among the group of Apigenin, Cannflavin. A. Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and BCL-2. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include brain, breast, colon, renal, liver, lung, pancreatic, prostate, leukemia, melanoma as well as any other cancers that overexpress the oncogenic factors inhibited by the cannabis flavonoids identified herein.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: October 12, 2021
    Assignee: Flavocure Biotech, Inc.
    Inventors: Henry Lowe, Ngeh J. Toyang
  • Patent number: 11129819
    Abstract: Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: September 28, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Matthew Duncton, Somasekhar Bhamidipati, Jiaxin Yu, Ihab Darwish, Rajinder Singh
  • Patent number: 11129830
    Abstract: Compositions and methods for the induction of cancer cell death. The compositions and methods of using them include use of compositions in therapy for the treatment of cancer and for the selective induction of apoptosis in cancer cells. The drug combinations described herein can be synergistic and can have lower neurotoxicity effects than the same amounts of other compounds and combinations of compounds and can be effective when a particular cancer has become resistant to previously administered therapies.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: September 28, 2021
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Jessie Peh
  • Patent number: 11103001
    Abstract: The present disclosure comprises methods and compositions comprising an extracted mineral element composition to modulate muscle and/or bone loss, or deleterious muscle tone change.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: August 31, 2021
    Assignee: CORE INTELLECTUAL PROPERTIES HOLDINGS, LLC
    Inventors: Luke Blotsky, Krys Bojanowski
  • Patent number: 11103468
    Abstract: Compounds useful in inhibiting endo-exonuclease activity and treating cancer have the formula (I) wherein R3 is selected from the group consisting of loweralkyl, oxyalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, aminoalkyl or a halogen; R4 is selected from the group consisting of H, loweralkyl, oxyalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, aminoalkyl or a halogen; and wherein R5 is a loweralkyl; or formula (II) wherein R1 is selected from the group consisting of loweralkyl, oxyalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, aminoalkyl or halogen; R2 is selected from the group consisting of H, loweralkyl, oxyalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, aminoalkyl or halogen; and wherein R5 is a loweralkyl comprising a linear carbon chain of at least two carbons connecting the first “O” to the second “O”.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: August 31, 2021
    Inventor: Terry Chow
  • Patent number: 11077094
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: August 3, 2021
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Patent number: 11065342
    Abstract: This invention relates to multi-specific molecules, such as long acting multi-specific antibodies. Also disclosed are relates methods.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 20, 2021
    Assignee: SHENZHEN ENDURING BIOTECH, LTD.
    Inventors: Shu-min Liu, Dechun Wu
  • Patent number: 11058690
    Abstract: A use of an inhibitor of the cytochrome bc1 complex for preparing a pharmaceutical composition which treats diseases related to smooth muscle spasms, inflammatory diseases, and relieves pain.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 13, 2021
    Assignee: BEIJING WEILANZHIYUAN MEDICAL TECHNOLOGY CO., LTD.
    Inventor: Yuwen Cong
  • Patent number: 11058660
    Abstract: A method of healing an external wound involves applying an external wound-healing agent to an external wound, or bringing the external wound-healing agent applied to a substrate into contact with an external wound, wherein the external wound-healing agent includes, as an active ingredient, at least one compound of a glycerol alkyl ester represented by defined Formula (I) or a diglycerol alkyl ester represented by defined Formula (II). In a further embodiment, the method involves bringing a fiber aggregate or a film into contact with an external wound, wherein the fiber aggregate or the film each includes a thermoplastic resin and at least one compound of the glycerol alkyl ester or the diglycerol alkyl ester.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: July 13, 2021
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Naosuke Kunimoto, Kenichi Suzuki, Kouya Kojima, Akira Hasegawa, Yasufumi Tsuchiya, Jun Kamada, Satoshi Yamasaki, Goro Kuwamura, Daisuke Hasegawa
  • Patent number: 11052069
    Abstract: The invention provides novel regimens of farnesoid X receptor (FXR) agonist and methods for modulating the activity of farnesoid X receptors (FXRs) using novel regimes of specific FXR agonists, in particular for treating or preventing fibrotic or cirrhotic diseases or disorders, such as liver diseases.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 6, 2021
    Assignee: Novartis AG
    Inventors: Bryan Laffitte, Andreas Bauer, Michael Badman, Jin Chen, Patrick Mueller, Rachel Soon
  • Patent number: 11020362
    Abstract: Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts and beta-hydroxybutyric acid are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB composition is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes beta-hydroxybutyric acid and a plurality of BHB salts selected from sodium, potassium, calcium, and magnesium. The BHB composition may include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long chain fatty acid source, vitamin D3, flavorant, or other excipient.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 1, 2021
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 11021443
    Abstract: The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 1, 2021
    Assignees: President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Bruce P. Bean, Clifford J. Woolf, Jinbo Lee, Sooyeon Jo, David Roberson, Sebastien Talbot
  • Patent number: 11000530
    Abstract: Compositions comprising at least two of a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), and an antibiotic find use in treating or preventing eye conditions in subjects in need thereof. Methods of treatment or prevention of eye conditions comprise administering an effective amount of the disclosed compositions to the affected eye(s). Methods of preparing a composition comprising an NSAID, a corticosteroid, and an antibiotic comprise separately complexing the NSAID and antibiotic with cyclodextrin.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 11, 2021
    Assignee: MURRAY AND POOLE ENTERPRISES LTD
    Inventor: Yosuf El-Shabrawi
  • Patent number: 11000525
    Abstract: There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 11, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Tord Bertil Inghardt, Petra Johannesson, Ulrik Jurva, Erik Michaelsson, Eva-Lotte Lindstedt-Alstermark, Nicholas Tomkinson, Jeffrey Paul Stonehouse, Li-Ming Gan
  • Patent number: 10987324
    Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 27, 2021
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, David Chernoff, Sangita Ghosh, Gregory T. Went, Timothy J. Fultz
  • Patent number: 10973783
    Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: April 13, 2021
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, David Chernoff, Sangita Ghosh, Gregory T. Went, Timothy J. Fultz
  • Patent number: 10973835
    Abstract: A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R1, R2, R3 and R4 are defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: April 13, 2021
    Assignees: The Penn State Research Foundation, Cold Spring Harbor Laboratory
    Inventors: Stephen J. Benkovic, Nicholas K. Tonks, Chun Yu Liu, Navasona Krishnan, Chunliang Liu
  • Patent number: 10966968
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on rosiglitazone therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: April 6, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Rene Braeckman, William Stirtan, Paresh Soni